Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial
Erin A. Bohula, Nicholas Marston, Andrea Ruzza, Sabina A. Murphy, Gaetano Maria De Ferrari, Rafael Díaz, Lawrence A. Leiter, Mary Elliott‐Davey, Huei Wang, Ajay Bhatia, Robert P. Giugliano, Marc S. Sabatine
Topics & Concepts
EvolocumabMedicineInternal medicineStroke (engine)Myocardial infarctionCardiologyClinical endpointPCSK9PopulationRandomized controlled trialApolipoprotein BCholesterolLipoproteinApolipoprotein A1LDL receptorEngineeringEnvironmental healthMechanical engineeringLipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesProtease and Inhibitor Mechanisms